SCHEMBL2462906

SCHEMBL2462906

CC(C)O[CH]c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.38
TRPA1 O75762 1/20 0.37
ALDH1A1 P00352 3/20 0.36
TSHR P16473 1/20 0.36
MAOB P27338 1/20 0.36
CYP2A6 P11509 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
AHR P35869 1/20 0.35
NPC1 O15118 1/20 0.35
MTOR P42345 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6110348 0.78 MEN1 (0.38) HTR2ATRPA1NPC1MTORTP53
SCHEMBL23134220 0.76 MAOB (0.44) HTR2ATRPA1MAOBAHRNPC1
SCHEMBL419698 0.76 MAOB (0.44) HTR2ATRPA1MAOBAHRNPC1
SCHEMBL7325160 0.76 TRPA1 (0.39) TRPA1ALDH1A1TSHRMAOBCYP2A6
SCHEMBL1407382 0.75 ALDH1A1 (0.36) TRPA1ALDH1A1TSHRMAOBCYP2A6
SCHEMBL11627744 0.73 IDO1 (0.42) TSHRTP53CYP2D6CYP2C9MAPK1
SCHEMBL5580369 0.73 IDO1 (0.38) TRPA1L3MBTL1MAPK1
SCHEMBL15797751 0.73 MAOB (0.52) HTR2ATRPA1ALDH1A1MAOBAHR
SCHEMBL10878968 0.72 ALDH1A1 (0.36) HTR2AALDH1A1NPC1MTORTP53
SCHEMBL6021371 0.72 ALDH1A1 (0.38) ALDH1A1TSHRCYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044041-B2 e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-10-25 US claimed
EP-2131656-A2 PHTHALAZINE DERIVATIVES Forest Laboratories Holdings Limited (BM) 2009-12-16 EP claimed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 US claimed
WO-2008061108-A2 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO claimed
WO-2006103119-A2 TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-05 WO claimed
US-11718758-B2 Aqueous dispersion of colored particles MITSUBISHI PENCIL COMPANY, LIMITED (JP) 2023-08-08 US disclosed
EP-3725854-B1 COLORED PARTICLE AQUEOUS DISPERSION MITSUBISHI PENCIL CO (JP) 2023-07-05 EP disclosed
CN-111465662-B Aqueous dispersion of coloured particles 三菱铅笔株式会社 2023-05-26 CN disclosed
US-20210071006-A1 AQUEOUS DISPERSION OF COLORED PARTICLES MITSUBISHI PENCIL COMPANY, LIMITED (JP) 2021-03-11 US disclosed
CN-108473784-B Polyfunctional polymerizable compound and coloring composition 富士胶片和光纯药株式会社 2021-01-12 CN disclosed
EP-3725854-A1 COLORED PARTICLE AQUEOUS DISPERSION MITSUBISHI PENCIL COMPANY, LIMITED (JP) 2020-10-21 EP disclosed
CN-111465662-A Aqueous dispersions of pigmented particles 三菱铅笔株式会社 2020-07-28 CN disclosed
WO-2006103119-A2 TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-05 WO disclosed
US-20040235761-A1 Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue TOYAMA CHEMICAL CO., LTD. (JP) 2004-11-25 US disclosed
EP-1417967-A1 NOVEL VIRUS PROLIFERATION INHIBITION/VIRUCIDAL METHOD AND NOVEL PYRADINE NUCLEOTIDE/PYRADINE NUCLEOSIDE ANALOGUE TOYAMA CHEMICAL CO., LTD. (JP) 2004-05-12 EP disclosed
EP-1304325-A1 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-04-23 EP disclosed
US-5853699-A Use of tetra azacycle complexes as x-ray diagnostic agents for the liver and gallbladder SCHERING AKTIENGESELLSCHAFT (DE) 1998-12-29 US disclosed
EP-0794799-A2 USE OF METAL COMPLEXES AS LIVER AND GALL BLADDER RADIODIAGNOSIS AGENTS IN COMPUTER TOMOGRAPHY SCHERING AKTIENGESELLSCHAFT (DE) 1997-09-17 EP disclosed
WO-1996016677-A2 USE OF METAL COMPLEXES AS LIVER AND GALL BLADDER RADIODIAGNOSIS AGENTS IN COMPUTER TOMOGRAPHY SCHERING AKTIENGESELLSCHAFT (DE) 1996-06-06 WO disclosed
US-3974280-A Benzothiophenes CIBA-GEIGY CORPORATION (US) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146547-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 HTR2A 1998/4885TRPA1 3257/4885ALDH1A1 3613/4885
US-20040235761-A1 Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue CDK5, NT5C3B, CDK15 HTR2A 1572/4885TRPA1 3619/4885ALDH1A1 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.